EraGen Partners with Illumina to Develop Molecular Dx Assays | GenomeWeb

NEW YORK (GenomeWeb News) – EraGen Biosciences said today that it has formed a strategic partnership with Illumina to develop high-throughput, multiplexed clinical assays.

Under the agreement, EraGen, based in Madison, Wis., has non-exclusively licensed the use of Illumina's BeadXpress platform to develop and commercialize molecular-based, high-throughput, clinical assays using EraGen's MultiCode-PLx technology.

Meantime, Illumina has non-exclusively licensed EraGen's MultiCode-PLx technology for the life sciences, research, and clinical markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.